| Biomarker ID | 1175 |
| PMID | 23861782 |
| Year | 2013 |
| Biomarker | PCA3 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Upregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | Base Model + PCA3: OR: [1.02 (95% CI: 1.01 to 1.02)] |
| Effect on Pathways | NA |
| Experiment | Prostate Cancer Vs No evidence of Maligancy |
| Type of Biomarker | Diagnostic |
| Cohort | Population of 300, such that 108 had Prostate Cancer and 192 had no evidence of malignancy were considered for the study |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.73 (95% CI: 0.68 to 0.79) |
| Accuracy | NA |
| Level Of Significance | p <0.001 |
| Method Used | Assays |
| Clinical | No |
| Remarks | PCA3 score was calculated as: (mRNA PCA3)/(mRNA PSA) X 1000. ; Patients with PSA in range 2-10ng/ml were chosen for this analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |